A graduate of Emory University School of Medicine, Dr. Levetan went on to be Professor and Chief of Endocrinology, Diabetes at Hahnemann Medical College and the Medical College of Pennsylvania, now Drexel University College of Medicine. She has a private practice in Endocrinology at Chestnut Hill Hospital in Philadelphia.
In 2004, Dr. Levetan co-founded CureDM, Inc., and served as its Chief Scientific and Medical Officer and lead scientist. CureDM’s intellectual property portfolio was licensed to Sanofi-Aventis in 2010.
In 2007, Dr. Levetan received the American College of Endocrinology‘s Highest Distinction in Clinical Endocrinology Award that is presented annually to the endocrinologist recognized as having achieved distinction in the field of clinical endocrinology and has a sustained record of devotion to teaching the art and science of endocrinology.
In 2009, The Philadelphia Business Journal named Dr. Levetan as one of the top Business Women for having successfully funded and led CureDM’s scientific research, which included an innovative and patented new drug for reversal of type 1 and 2 diabetes.
Dr. Levetan has served as an associate editor of the journals, Clinical Diabetes and Diabetes Forecast. She has been published in many medical journals including the American Journal of Medicine. She received the Roche Diagnosed prestigious award for innovative diabetes research and has been an invited visiting scholar at Harvard University’s Joslin Diabetes Center, as well as an invited Grand Rounds speaker at the Harvard Hospitals. Dr. Levetan has led research teams in the area of “methods to prevent and reverse diabetes,” and was an investigator on the NIH’s Diabetes Prevention Program and Women’s Health Initiative. She was also a co-chair of the American College of Endocrinology’s Diabetes Outpatient and Inpatient Consensus Conferences, which established the first specific goals for patients both before and after meals.
Dr. Levetan has been an expert on the NIH’s international consensus panel on inpatient management of diabetes and has served on the steering committee of the NIH and CDC’s National Diabetes Education Program (NDEP). She served on the Board of Directors of the American Association of Clinical Endocrinologists and was on the Board of Trustees of the American College of Endocrinology.
In 2013, Dr. Levetan founded Perle Bioscience and is the Chief Scientific Officer for the company.